Is the fat anterior to the psoas muscle, below the lower pole of the kidney, typically considered perirenal or pararenal fat, and is it an uncommon site for lymph node metastasis in renal cell carcinoma (kidney cancer)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 20, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The fat anterior to the psoas muscle below the lower pole of the kidney is typically considered pararenal fat, not perirenal fat, and is an uncommon site for lymph node metastasis in renal cell carcinoma (kidney cancer). When considering the anatomical factors that provide prognostic information in renal cell carcinoma, as outlined in the European Association of Urology guidelines on renal cell carcinoma: the 2022 update 1, it's crucial to distinguish between perirenal and pararenal fat due to their implications on tumor staging and surgical management. The perirenal fat, contained within Gerota's fascia, directly surrounds the kidney, whereas the pararenal fat lies outside Gerota's fascia and extends anteriorly to the psoas muscle. Key points to consider include:

  • The distinction between perirenal and pararenal fat is critical because tumor extension into the perirenal fat (within Gerota's fascia) represents a T3a stage in kidney cancer, whereas involvement of pararenal fat indicates more extensive spread.
  • Kidney cancer typically spreads first to the renal hilar, paracaval, para-aortic, and retroperitoneal lymph nodes before affecting more distant nodes, making lymph node metastasis in the pararenal fat an uncommon occurrence.
  • During surgical management of kidney cancer, the entire kidney with its surrounding perirenal fat is typically removed en bloc within Gerota's fascia, while the pararenal fat often remains undisturbed unless there's evidence of more extensive disease, as suggested by the guidelines 1. Understanding these anatomical and clinical considerations is essential for the effective management of renal cell carcinoma, emphasizing the importance of accurate staging and surgical planning based on the latest evidence, such as that provided by the European Association of Urology guidelines 1.

From the Research

Fat Anterior to the Psoas Muscle

  • The fat anterior to the psoas muscle, below the lower pole of the kidney, is typically considered pararenal fat, as it is located outside the renal fascia that encloses the kidney and the perirenal fat [not explicitly stated in 2,3,4,5,6].

Lymph Node Metastasis in Renal Cell Carcinoma

  • Lymph node metastasis is a common feature of disease progression in most solid organ malignancies, including renal cell carcinoma 3.
  • The presence of lymph node involvement in renal cell carcinoma doubles a patient's risk of distant metastasis and significantly reduces their 5-year survival 6.
  • The fat anterior to the psoas muscle is not typically considered a common site for lymph node metastasis in renal cell carcinoma, as lymph nodes are more commonly found in the renal hilum, paraaortic, and paracaval regions [not explicitly stated in 2,3,4,5,6].
  • However, there is limited information available on the specific location of lymph node metastasis in relation to the psoas muscle and pararenal fat [(2,4,6)].

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Solitary psoas muscle metastasis after radical nephrectomy for renal cell carcinoma.

International journal of urology : official journal of the Japanese Urological Association, 2005

Research

Primary malignant tumors of the iliopsoas compartment.

Journal of surgical oncology, 2004

Research

Assessing lymph node status in patients with kidney cancer.

Translational andrology and urology, 2018

Related Questions

Is the fat anterior to the psoas (muscle) below the lower pole of the kidney an uncommon location for lymph node metastasis in renal cell carcinoma (kidney cancer)?
Is fat anterior or lateral to the psoas (muscle) muscle caudal to the lower pole of the left kidney a common or uncommon site for lymph node metastasis in kidney cancer?
Is fat anterior to the psoas (muscle) caudal to the lower pole of the left kidney a common location for lymph node metastasis in kidney cancer?
Is fat anterior to the psoas (major muscle in the lower back) muscle below the lower pole of the left kidney an uncommon location for lymph node metastasis in renal cell carcinoma (kidney cancer)?
Is lymph node metastasis of kidney cancer uncommon in the perinephric fat anterior to the psoas muscle below the lower pole of the kidney?
Is the fat anterior to the psoas muscle, below the lower pole of the kidney, typically perirenal or pararenal fat, and is it an uncommon site for lymph node metastasis in renal cell carcinoma (kidney cancer)?
How often should liver function tests (LFTs), including liver enzymes, be monitored when initiating fezolinetant (NK1 receptor antagonist) in a postmenopausal patient?
What is the recommended frequency for checking laboratory tests in patients taking Depakote (valproate)?
Is the fat anterior to the psoas muscle (psoas major) below the lower pole of the kidney, specifically the perirenal fat (fat surrounding the kidney), an uncommon location for lymph node metastasis in renal cell carcinoma (kidney cancer)?
What thyroid function tests should be measured after thyroidectomy (thyroid removal)?
Is the fat anterior to the psoas muscle, below the lower pole of the kidney, which is part of the perirenal (perirenal) fat, an uncommon location for lymph node metastasis in kidney cancer?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.